Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Gastroenterology

Will PSC Come Back After a Liver Transplant? Explained

At a Glance

Primary sclerosing cholangitis (PSC) can return after a liver transplant in roughly 15% to 35% of patients. However, recurrent PSC progresses slowly, and long-term survival rates remain excellent. Controlling active inflammatory bowel disease is a key factor in protecting your new liver.

Yes, primary sclerosing cholangitis (PSC) can return after a liver transplant, a condition known as recurrent PSC (rPSC). While this is a valid fear for many patients, it is important to know that a liver transplant is highly successful for treating PSC. Even if the disease does come back, it typically progresses slowly, and the overall survival rates for patients are among the best of any group receiving a liver transplant.

How Likely is Recurrence?

Research shows that recurrent PSC affects approximately 15% to 35% of liver transplant recipients over time [1][2][3]. The likelihood of recurrence increases the longer you live with your new liver. At 5 years post-transplant, the recurrence rate is estimated between 8% and 15% [4][5]. By 10 years, that rate climbs to roughly 23% to 25% [2][1].

What Does This Mean for Your Health and Survival?

Despite the risk of recurrence, the long-term outlook for PSC patients after transplantation is excellent. The 5-year patient survival rate is typically between 83% and 89%, and the 10-year survival rate remains strong at roughly 65% to 79% [1][6][7]. In fact, liver transplant outcomes for PSC patients are superior to outcomes for many other liver diseases [8][9].

If rPSC does develop, it is generally a slow-moving condition. In the early stages, you might not feel any physical changes, which is why your medical team will monitor you proactively. They often use regular MRCP (Magnetic Resonance Cholangiopancreatography) imaging scans—frequently on an annual basis or at regular intervals determined by your doctor—to catch any changes to your bile ducts early [10].

However, you should not wait for your next scan if you begin to feel unwell. Contact your care team between scheduled visits if you notice a return of your previous PSC symptoms, such as:

  • New or worsening severe itching (pruritus)
  • Yellowing of your skin or eyes (jaundice)
  • Unexplained, profound fatigue
  • Pain in your upper right abdomen
  • Fever and chills, which could signal an infection

In cases where rPSC eventually causes the new liver to fail, a second transplant (re-transplantation) remains a viable and effective option [2][11].

Risk Factors for Recurrent PSC

While anyone transplanted for PSC can experience recurrence, researchers have identified several factors that can influence the risk:

  • Inflammatory Bowel Disease (IBD): Having active ulcerative colitis after your transplant significantly increases the risk of developing rPSC [12][4]. Conversely, patients who have had their colon removed (colectomy) prior to their liver transplant have a lower risk of disease recurrence [13][14].
  • Age at Transplant: Younger patients tend to have a higher risk of rPSC compared to older patients [12][15]. This may be due to having a more active immune system or simply living longer after the transplant, giving the disease more time to potentially return.
  • Surgical Technique: The way your surgeon connects your bile ducts during the transplant matters. A technique called Roux-en-Y (RY) hepaticojejunostomy (where the bile duct is attached directly to the small intestine) is often safer and associated with better outcomes for PSC patients compared to connecting the donor and recipient bile ducts directly [16]. You do not have to choose the surgery type yourself; your transplant surgeon will determine the safest approach based on your specific anatomy during the operation.
  • Medications: The choice of immunosuppression medication plays a complex role. Tacrolimus is the standard medication recommended to prevent your body from rejecting the new liver because it is highly successful at ensuring the long-term survival of the organ [17]. However, some research indicates it may be associated with a higher risk of rPSC compared to older anti-rejection medications [4][12]. Your care team will carefully balance these factors to give you the best overall outcome.

Looking Ahead

Because of the strong connection between the gut and the liver, managing any underlying inflammatory bowel disease is absolutely critical after a transplant. Your care team will closely monitor both your liver enzymes and your colon health. By staying on top of routine screenings, adhering strictly to your medication schedule, and communicating openly with your doctors about any new symptoms, you maximize the lifespan of your new liver.

Common questions in this guide

What are the chances of PSC returning after a liver transplant?
Recurrent PSC affects about 15% to 35% of liver transplant recipients over time. The risk increases the longer you live with your new liver, reaching roughly 23% to 25% by 10 years post-transplant.
What happens if PSC comes back after my transplant?
If PSC returns, it usually progresses very slowly. The long-term survival rates for patients remain excellent, and if the new liver eventually fails, a second transplant is often a viable option.
What are the symptoms of recurrent PSC?
Early stages often have no symptoms, but you may eventually experience severe itching, yellowing of the skin or eyes, extreme fatigue, upper right abdominal pain, or fever and chills.
How does having inflammatory bowel disease affect my risk for recurrent PSC?
Having active inflammatory bowel disease, particularly ulcerative colitis, significantly increases the risk of PSC returning after a transplant. Managing your bowel disease closely with your care team is critical to protecting your new liver.
How will my doctors monitor for recurrent PSC?
Your medical team will monitor you proactively, typically using regular MRCP imaging scans of your bile ducts. These regular scans help doctors catch any changes early, even before you feel physical symptoms.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What type of biliary reconstruction do you anticipate using for my transplant based on my anatomy?
  2. 2.How frequently will you monitor me for recurrent PSC using MRCP scans after the transplant?
  3. 3.Since I also have inflammatory bowel disease, how will my post-transplant care team coordinate with my gastroenterologist?
  4. 4.What immunosuppression regimen do you recommend for someone with my specific risk factors, and how do we balance preventing rejection with minimizing rPSC risk?
  5. 5.How often will I need colonoscopies after the transplant to monitor my colon health?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

What is the Best Diet for Primary Sclerosing Cholangitis?CA 19-9 Test: Bile Duct Cancer Screening in PSCWhat Experimental Treatments Are in PSC Clinical Trials?What is the Difference Between IgG4-SC and PSC?Why is Balloon Dilation Preferred Over Stents for PSC?What Does a FibroScan Score Over 10.5 kPa Mean for PSC?When Should PSC Patients Have Gallbladder Polyps Removed?Is High-Dose URSO Safe for Primary Sclerosing Cholangitis?PSC: Can Recurrent Cholangitis Raise My MELD Score?What Is the Difference Between Small & Large Duct PSC?What Are the Third-Line Treatments for Severe PSC Itching?When to Take Cholestyramine with Other PSC MedicationsWhy Do You Need A Colonoscopy For PSC Without Symptoms?

References

References (17)
  1. 1

    Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis.

    Hildebrand T, Pannicke N, Dechene A, et al.

    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2016; (22(1)):42-52 doi:10.1002/lt.24350.

    PMID: 26438008
  2. 2

    Timing, Management, and Outcomes of Liver Transplantation in Primary Sclerosing Cholangitis.

    Martin EF, Levy C

    Seminars in liver disease 2017; (37(4)):305-313 doi:10.1055/s-0037-1608655.

    PMID: 29272893
  3. 3

    Recurrence of primary sclerosing cholangitis after liver transplantation - analysing the European Liver Transplant Registry and beyond.

    Visseren T, Erler NS, Polak WG, et al.

    Transplant international : official journal of the European Society for Organ Transplantation 2021; (34(8)):1455-1467 doi:10.1111/tri.13925.

    PMID: 34028110
  4. 4

    Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation: A French National Cohort Study Including 571 Patients.

    Veyre F, De Martin E, Erard D, et al.

    The American journal of gastroenterology 2026; (121(6)):1401-1413 doi:10.14309/ajg.0000000000003659.

    PMID: 40736679
  5. 5

    Long-term (15 y) complications and outcomes after liver transplantation for primary sclerosing cholangitis: Impact of donor and recipient factors.

    Mouchli MA, Osman MK, Busebee B, et al.

    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2025; (31(6)):781-792 doi:10.1097/LVT.0000000000000523.

    PMID: 39451100
  6. 6

    Primary sclerosing cholangitis associated with inflammatory bowel disease: an update.

    Rossi RE, Conte D, Massironi S

    European journal of gastroenterology & hepatology 2016; (28(2)):123-31 doi:10.1097/MEG.0000000000000532.

    PMID: 26636407
  7. 7

    Donor age (≥45 years) and reduced immunosuppression are associated with the recurrent primary sclerosing cholangitis after liver transplantation - a multicenter retrospective study.

    Akamatsu N, Hasegawa K, Egawa H, et al.

    Transplant international : official journal of the European Society for Organ Transplantation 2021; (34(5)):916-929 doi:10.1111/tri.13852.

    PMID: 33629379
  8. 8

    Do Patients with Autoimmune Conditions Have Less Access to Liver Transplantation despite Superior Outcomes?

    Keeling SS, McDonald MF, Anand A, et al.

    Journal of personalized medicine 2022; (12(7)) doi:10.3390/jpm12071159.

    PMID: 35887656
  9. 9

    Primary sclerosing cholangitis.

    Rabiee A, Silveira MG

    Translational gastroenterology and hepatology 2021; (6()):29 doi:10.21037/tgh-20-266.

    PMID: 33824933
  10. 10

    Early MRCP surveillance for recurrent primary sclerosing cholangitis after liver transplantation: a prospective imaging study.

    Bik E, Stadnik A, Wronka KM, et al.

    Scientific reports 2026; (16(1)).

    PMID: 41963542
  11. 11

    Outcome of Liver Retransplantation in Patients With Primary Sclerosing Cholangitis.

    Molinaro A, Engesæter LK, Jorns C, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2025; (45(1)):e16214 doi:10.1111/liv.16214.

    PMID: 39679639
  12. 12

    Risk factors for recurrent primary sclerosing cholangitis after liver transplantation.

    Ravikumar R, Tsochatzis E, Jose S, et al.

    Journal of hepatology 2015; (63(5)):1139-46.

    PMID: 26186988
  13. 13

    Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study.

    Lindström L, Jørgensen KK, Boberg KM, et al.

    Scandinavian journal of gastroenterology 2018; (53(3)):297-304 doi:10.1080/00365521.2017.1421705.

    PMID: 29301479
  14. 14

    The impact of ileal pouch-anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis.

    Trivedi PJ, Reece J, Laing RW, et al.

    Alimentary pharmacology & therapeutics 2018; (48(3)):322-332 doi:10.1111/apt.14828.

    PMID: 29882252
  15. 15

    Does mucosal inflammation drive recurrence of primary sclerosing cholangitis in liver transplantion recipients with ulcerative colitis?

    Dekkers N, Westerouen van Meeteren M, Wolterbeek R, et al.

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2020; (52(5)):528-533 doi:10.1016/j.dld.2020.02.006.

    PMID: 32147286
  16. 16

    Updated Systematic Review and Meta-Analysis of Duct-to-duct Versus Hepaticojejunostomy Reconstruction After Liver Transplantation for Primary Sclerosing Cholangitis.

    Faleiro MD, de M Ogawa T, Correia PP, et al.

    Transplantation 2026; (110(4)):e774-e784 doi:10.1097/TP.0000000000005639.

    PMID: 41572464
  17. 17

    Cyclosporine vs. tacrolimus after liver transplantation for primary sclerosing cholangitis - a propensity score-matched intention-to-treat analysis.

    Åberg F, Sallinen V, Tuominen S, et al.

    Journal of hepatology 2024; (80(1)):99-108 doi:10.1016/j.jhep.2023.08.031.

    PMID: 37722533

This page is for informational purposes only and does not replace professional medical advice. Always discuss transplant risks, monitoring, and outcomes with your transplant team.

Get notified when new evidence is published on Primary sclerosing cholangitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.